Cargando…
Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris
Acne vulgaris is a common, multifactorial, inflammatory skin disease affecting the pilosebaceous unit. Topical therapy is the first choice in the treatment of mild to moderate acne, and azelaic acid (AZA) is one of the most commonly used drugs. The aim of this study was to evaluate the safety and ef...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073278/ https://www.ncbi.nlm.nih.gov/pubmed/33923739 http://dx.doi.org/10.3390/pharmaceutics13040567 |
_version_ | 1783684093446193152 |
---|---|
author | Tomić, Ivona Miočić, Sandra Pepić, Ivan Šimić, Dubravka Filipović-Grčić, Jelena |
author_facet | Tomić, Ivona Miočić, Sandra Pepić, Ivan Šimić, Dubravka Filipović-Grčić, Jelena |
author_sort | Tomić, Ivona |
collection | PubMed |
description | Acne vulgaris is a common, multifactorial, inflammatory skin disease affecting the pilosebaceous unit. Topical therapy is the first choice in the treatment of mild to moderate acne, and azelaic acid (AZA) is one of the most commonly used drugs. The aim of this study was to evaluate the safety and efficacy of a low-dose azelaic acid nanocrystal (AZA-NC) hydrogel in the treatment of mild to moderate facial acne. The study was designed as a double-blind, randomized controlled trial. Patients were randomized to treatment with AZA-NC hydrogel, 10%, or AZA cream, 20%, administered in quantities of approximately 1 g twice daily for 8 weeks. Efficacy of therapy was measured by the number of lesions and safety by the frequency and severity of adverse events. At week 8, the success rate of treatment with AZA-NC hydrogel, 10%, was 36.51% (p < 0.001) versus 30.37% (p < 0.001) with AZA cream. At week 8, treatment with AZA-NC hydrogel, 10%, resulted in a significant reduction in total inflammatory lesions from baseline of 39.15% (p < 0.001) versus 33.76% (p < 0.001) with AZA cream, and a reduction in non-inflammatory lesions from baseline of 34.58% (p < 0.001) versus 27.96% (p < 0.001) with AZA cream, respectively. The adverse event rate was low and mostly mild. |
format | Online Article Text |
id | pubmed-8073278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80732782021-04-27 Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris Tomić, Ivona Miočić, Sandra Pepić, Ivan Šimić, Dubravka Filipović-Grčić, Jelena Pharmaceutics Article Acne vulgaris is a common, multifactorial, inflammatory skin disease affecting the pilosebaceous unit. Topical therapy is the first choice in the treatment of mild to moderate acne, and azelaic acid (AZA) is one of the most commonly used drugs. The aim of this study was to evaluate the safety and efficacy of a low-dose azelaic acid nanocrystal (AZA-NC) hydrogel in the treatment of mild to moderate facial acne. The study was designed as a double-blind, randomized controlled trial. Patients were randomized to treatment with AZA-NC hydrogel, 10%, or AZA cream, 20%, administered in quantities of approximately 1 g twice daily for 8 weeks. Efficacy of therapy was measured by the number of lesions and safety by the frequency and severity of adverse events. At week 8, the success rate of treatment with AZA-NC hydrogel, 10%, was 36.51% (p < 0.001) versus 30.37% (p < 0.001) with AZA cream. At week 8, treatment with AZA-NC hydrogel, 10%, resulted in a significant reduction in total inflammatory lesions from baseline of 39.15% (p < 0.001) versus 33.76% (p < 0.001) with AZA cream, and a reduction in non-inflammatory lesions from baseline of 34.58% (p < 0.001) versus 27.96% (p < 0.001) with AZA cream, respectively. The adverse event rate was low and mostly mild. MDPI 2021-04-16 /pmc/articles/PMC8073278/ /pubmed/33923739 http://dx.doi.org/10.3390/pharmaceutics13040567 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tomić, Ivona Miočić, Sandra Pepić, Ivan Šimić, Dubravka Filipović-Grčić, Jelena Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris |
title | Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris |
title_full | Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris |
title_fullStr | Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris |
title_full_unstemmed | Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris |
title_short | Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris |
title_sort | efficacy and safety of azelaic acid nanocrystal-loaded in situ hydrogel in the treatment of acne vulgaris |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073278/ https://www.ncbi.nlm.nih.gov/pubmed/33923739 http://dx.doi.org/10.3390/pharmaceutics13040567 |
work_keys_str_mv | AT tomicivona efficacyandsafetyofazelaicacidnanocrystalloadedinsituhydrogelinthetreatmentofacnevulgaris AT miocicsandra efficacyandsafetyofazelaicacidnanocrystalloadedinsituhydrogelinthetreatmentofacnevulgaris AT pepicivan efficacyandsafetyofazelaicacidnanocrystalloadedinsituhydrogelinthetreatmentofacnevulgaris AT simicdubravka efficacyandsafetyofazelaicacidnanocrystalloadedinsituhydrogelinthetreatmentofacnevulgaris AT filipovicgrcicjelena efficacyandsafetyofazelaicacidnanocrystalloadedinsituhydrogelinthetreatmentofacnevulgaris |